Table 10.

Studies examining peri-hepatic lymphadenectomy in patients undergoing liver resection for metastatic colon cancer

Study (n=lymphadenectomy patients)	Neoadjuvant chemo	# LN harvested (range)	% with (+)PHLN	OS (−) PHLN	OS (+) PHLN
Bennett et al. 2008 (n=59)	50/59 (85%)	3.2 (1–11)	22/59 (37%)	3-year 75%	3-year 25% (H&E+), 76% (IHC+)
Okuno et al. 2017 (n=174)	154/174 (89%)	NR	54/174 (31%)	71 months	13.8 months
Nanji et al. 2016 (n=103)	22/103 (21%)	2.2 (1–15)	30/103 (29%)	46 months	25 months
Bradatsch et al. 2016 (n=20)	15/20 (75%)	5 (NR)	0/20 (0%)	NR	NA
Pindak et al. 2017 (n=59)	0/59 (0%)	4.6 (0–13)	7/59 (12%)	67 months	30 months

Notes: LN, lymph node; NA, not applicable; NR, not reported; OS, median overall survival; PHLN, peri-hepatic lymph node